NEOMED announced today that it has entered into definitive agreements with GSK to create the Biologics and Vaccine Centre of Excellence in Laval, forming a unique platform that will support the biopharmaceutical sector. These agreements concern the transaction of purchase and sale of assets, the lease and sub-lease of the facility to NEOMED and the R&D collaboration between the two entities. With these agreements, NEOMED will pursue its strategic plan and extend its expertise in the biologics and vaccine sector.
“We are thrilled about the unique opportunity this project is creating for pharmaceutical research in Quebec. This new partnership is testimony that our sector is dynamic and continues to innovate. In the last three years, NEOMED has shown its flexibility to quickly adapt and its capability to maintain, in Quebec, the exceptional expertise developed in large pharmaceutical companies. Under the leadership of this new Centre of Excellence, we will continue to support academic innovation and allow the growth of small and medium-sized companies,” said NEOMED President and CEO, Max Fehlmann.
Sixty employees are currently working at the new NEOMED biologics and vaccine division. The research facility will be transformed into a multi-tenant hub of independent, small and medium-sized enterprises focusing on the development of biologics and vaccines. NEOMED will also be creating a specialized contract research organization (CRO) that will market its biology and clinical immunology services to the business community and to GSK for at least three years. Under the terms of the agreements, GSK is investing $47 million in the Centre of Excellence.
– 30 –
NEOMED is a not-for-profit organization whose mission is to foster the development of promising therapeutic approaches emerging from academia and biotechnology companies. Created in 2012, NEOMED supports the development of projects up to the stage of human proof of concept. NEOMED operates in a virtual mode using the services of the NEOMED Institute. The Institute is an open-access drug discovery hub with two high-tech research and development facilities; one in Technoparc Montréal’s Saint-Laurent Campus, specializing in small molecule therapeutics, and the other facility, NEOMED’s biologics and vaccine division, is located in Laval.
NEOMED is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de l’Innovation et des Exportations du Québec, and the Networks of Centres of Excellence (NCE) of Canada. For more information, please visit our website: www.neomed.ca.
Source : Christine O’Doherty
Download the PDF